Best Practices in the Treatment and Management of Metastatic Melanoma: Expert Perspectives in Immunotherapy

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 1, 2021 to March 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

Melanoma is the most serious type of skin cancer. It will be found in approximately 73,870 people in the US in 2020 according to the National Cancer Institute. While it is the least common amongst skin cancers, it is by far the most deadly, with 9,940 people expected to die in 2020. Both of those numbers have been rising in recent years. Fortunately for patients with metastatic melanoma, significant progress has been made in the treatment of this deadly disease over the past few years, especially in the area of immunotherapies. This webinar on recent advances in the treatment and management of metastatic melanoma will provide attendees with updated treatment strategies, guidelines, and successful evidence-based treatment approaches from recent clinical data.

Upon completion of this activity, participants will be able to:

  • Detail approaches to identify patients for immunotherapy and stratify risk in the adjuvant-treatment setting of melanoma

  • Explore recent clinical data on checkpoint inhibitors in the first-line treatment in metastatic melanoma

  • Examine the role of Anti–PD-1 immunotherapy in metastatic melanoma

  • Identify appropriate adjuvant therapy for the treatment of a patient with cutaneous melanoma based on patient- and disease-specific factors

  • Evaluate common toxicities associated with checkpoint inhibitors in metastatic melanoma and describe best practices for their management

  • Assess the pharmacoeconomic impact of current and emerging immunotherapies for the treatment of metastatic melanoma


Faculty: Jeffrey S. Weber MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center


Dr. Weber serves as a consultant for Merck, Genentech, AstraZeneca, Pfizer, Regeneron, GSK, Alkermes, Novartis, Celldex, Incyte and EMD Serono. He serves on an advisory board for Bristol-Myers Squibb, Merck, GSK, Novartis, Moderna and Astra Zeneca. He owns stocks in CytoMx, Biond and Immunimax. He has received grant/research support from BMS, Merck, GSK, Novartis, Moderna and AstraZeneca. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue